PD-L1 SP263 Clone Test USA - $300 USD | Immunotherapy Biomarker Testing | Cancer Treatment Response
Sale!

PD-L1 SP263 Clone Test

Original price was: $450.Current price is: $300.

-33%

The PD-L1 SP263 Clone test is a crucial immunohistochemistry (IHC) biomarker analysis that detects programmed death-ligand 1 protein expression in cancer cells. This specialized test helps oncologists determine if patients are likely to respond to immunotherapy treatments, particularly immune checkpoint inhibitors. By measuring PD-L1 levels, the test provides valuable insights for personalized cancer therapy decisions. The test is performed on tissue blocks with results available in 6 days. This $300 USD test is essential for patients with various cancers including lung cancer, melanoma, and other solid tumors considering immunotherapy options. Understanding your PD-L1 status can significantly impact treatment success and outcomes.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

PD-L1 SP263 Clone Test: Comprehensive Immunotherapy Biomarker Analysis

Understanding the PD-L1 SP263 Clone Test

The PD-L1 SP263 Clone test represents a groundbreaking advancement in precision oncology, providing critical insights into a patient’s potential response to immunotherapy treatments. This specialized immunohistochemistry (IHC) test specifically detects and quantifies the programmed death-ligand 1 (PD-L1) protein expression in cancer cells, serving as a vital biomarker for immune checkpoint inhibitor therapy selection.

What Does the PD-L1 SP263 Clone Test Measure?

This sophisticated diagnostic test precisely measures the presence and intensity of PD-L1 protein expression on tumor cells and immune cells within the tumor microenvironment. The SP263 clone represents a highly specific antibody that binds to PD-L1, allowing pathologists to accurately assess:

  • Percentage of tumor cells expressing PD-L1
  • Pattern and intensity of PD-L1 staining
  • Tumor proportion score (TPS) for treatment eligibility
  • Combined positive score (CPS) for comprehensive assessment

Who Should Consider PD-L1 SP263 Clone Testing?

This test is particularly important for patients diagnosed with various cancer types who are considering immunotherapy as part of their treatment plan. Key candidates include:

  • Patients with non-small cell lung cancer (NSCLC) evaluating immunotherapy options
  • Individuals with melanoma considering immune checkpoint inhibitors
  • Patients with bladder cancer, head and neck cancers, or other solid tumors
  • Those who have failed conventional chemotherapy treatments
  • Individuals seeking personalized cancer treatment approaches

Clinical Benefits of PD-L1 SP263 Clone Testing

Understanding your PD-L1 status through this specialized test offers numerous clinical advantages:

  • Personalized Treatment Selection: Guides oncologists in choosing the most effective immunotherapy drugs
  • Improved Response Prediction: Helps predict likelihood of positive response to immune checkpoint inhibitors
  • Cost-Effective Treatment Planning: Avoids unnecessary immunotherapy expenses for unlikely responders
  • Enhanced Survival Outcomes: Increases chances of successful treatment by matching patients with appropriate therapies
  • Comprehensive Cancer Management: Provides valuable prognostic information for treatment planning

Understanding Your Test Results

Your PD-L1 SP263 Clone test results will provide critical information about your cancer’s characteristics:

  • Positive Result: Indicates high PD-L1 expression, suggesting potential benefit from immunotherapy
  • Negative Result: Suggests low PD-L1 expression, which may indicate alternative treatment approaches
  • Intermediate Results: May require additional clinical considerations and multidisciplinary review

Your oncologist will interpret these results in the context of your specific cancer type, stage, and overall health to develop the most effective treatment strategy.

Test Pricing and Availability

Test Component Price (USD)
Discount Price $300
Regular Price $450

Test Specifications

  • Turnaround Time: 6 days
  • Sample Type: Tissue Blocks
  • Methodology: Immunohistochemistry (IHC)
  • Test Components: Properly packed and previously labelled slides and blocks with clinical details and proper requisition form

Pre-Test Instructions

The PD-L1 SP263 Clone test requires a Doctor’s prescription for most cases. However, prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad. Our team ensures proper handling and processing of your tissue samples to maintain sample integrity and testing accuracy.

Nationwide Availability

We have branches across all major cities in the USA, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing results regardless of location.

Take Control of Your Cancer Treatment Journey

Don’t leave your treatment decisions to chance. The PD-L1 SP263 Clone test provides the critical information needed to make informed decisions about your cancer care. With immunotherapy revolutionizing cancer treatment, understanding your PD-L1 status has never been more important.

Ready to schedule your PD-L1 SP263 Clone test? Call or WhatsApp us today at +1(267) 388-9828 to book your appointment and take the first step toward personalized cancer treatment.

SKU: 9b1c93a6864c Category: